<DOC>
	<DOCNO>NCT02678520</DOCNO>
	<brief_summary>Compare incidence acute rectal , bladder acute toxicity 3-D Conformal Radiation Therapy ( RT/CRT ) Intensity Modulated Radiation Therapy ( IMRT ) Post-Prostatectomy Prostate Cancer Patients treat post-operative radiation therapy</brief_summary>
	<brief_title>Clinical Trial Comparing 3-D RT vs. IMRT Post- Prostatectomy Prostate Cancer Patients</brief_title>
	<detailed_description>In 2015 , American Cancer Society estimate almost 220,800 men expect diagnosed prostate cancer , 27,540 men expect die disease . Curative treatment prostate cancer consist either surgery ( i.e. , radical prostatectomy ) radiation therapy ( RT ) . Approximately one-third men undergo prostatectomy require post-operative adjuvant salvage RT . During last 2 decade , technique use deliver RT evolve 2-D RT 1980 's early 1990 's , 3-D conformal RT ( 3-D CRT ) late 1990 's , intensity modulate radiation therapy ( IMRT ) within last decade . To date , randomize prospective head head comparison 3-D CRT IMRT assess toxicity difference ever conduct treatment post-prostatectomy prostate cancer patient . Retrospective evidence suggest comparable acute late genitourinary ( GU ) gastrointestinal ( GI ) toxicity . In addition , postoperative randomize trial investigate hormonal therapy ( HT ) RT publish , three prior phase III study men treat definitively prostate cancer , one Radiation Therapy Oncology Group ( RTOG ) ( 86-10 ) , one investigator Harvard , one Trans-Tasman Radiation Oncology Group , conclude neoadjuvant concurrent short-term hormonal therapy ( i.e. , 4-6 month ) RT reduce cause-specific mortality compare RT alone . The purpose study estimate , correlate , compare incidence acute rectal , bladder acute toxicity 3-D CRT IMRT prostate cancer patient treat post-operative radiation therapy , quantify , compare , correlate dose volume histogram ( DVH ) dose ( e.g. , Vmean , Vmedian , V25 , V50 , V75 ) surround critical organ ( i.e. , rectum bladder ) 3-D CRT IMRT , measure , compare , correlate quality life score participant use EORTC Quality Live Questionnaires ( QLQ ) , call `` QLQ-C30 '' `` EPIC-26 '' . These survey instrument measure quality life difference study ; comparison do 3-D CRT IMRT treatment arm . Hormonal therapy also require patient high risk disease ( adjuvant salvage group ) per standard care patient low risk disease , explore study . There 2 arm ( group ) study : Arm 1 : 3-D Conformal Radiation Therapy ( plus hormonal therapy ) Arm 2 : Intensity Modulated Radiation Therapy ( plus hormonal therapy )</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>INCLUSION Criteria : Subjects must meet inclusion criterion participate study . Histologically document adenocarcinoma prostate . Status post radical prostatectomy sample pelvic lymph node histologically confirm adenocarcinoma prostate , patient fall either `` adjuvant low high risk group '' `` salvage low high risk group '' indicate . In case patient undergo prostatectomy without sample pelvic lymph node , patient also consider eligible find negative pelvic CT MRI scan show evidence lymphatic nodal metastasis prostatectomy . `` Adjuvant High Risk Group '' patient undetectable persistent/decreasing PSA level ( start therapy ) MUST able start radiation therapy treatment within 6 month radical prostatectomy least ONE 3 disease feature : Pathologic T2N0 ( clinical evidence metastasis ) Gleason Score ≥ 8 Pathologic T3aN0 ( clinical evidence metastasis ) ExtraCapsular Extension Gleason Score ≥ 8 Pathologic T3bN0 ( clinical evidence metastasis ) Gleason Score `` Salvage High Risk Group '' patient experience PSA failure ( define least 1 detectable PSA level &gt; 0.2 ng/ml least 2 consecutive increase PSA level baseline least 1 month apart radical prostatectomy ) least ONE 4 follow feature : Pathologic T3bN0 disease ( clinical evidence metastasis ) , Pathologic T23aN0 disease ( clinical evidence metastasis ) Gleason Score ≥ 8 , Pathologic T23aN0 disease ( clinical evidence metastasis ) PSA Doubling Time ≤ 10 month , Pathologic T23aN0disease ( clinical evidence metastasis ) PreRT PSA level ≥ 1.0 ng/ml `` Adjuvant Low Risk Group '' patient undetectable persistent/decreasing PSA level ( start therapy ) MUST able start radiation therapy treatment within 6 month radical prostatectomy least ONE 2 disease feature : Pathologic T2N0 ( clinical evidence metastasis ) , Gleason Score ≤ 7 , positive margin Pathologic T3aN0 ( clinical evidence metastasis ) ExtraCapsular Extension , Gleason Score ≤ 7 , without positive margin `` Salvage Low Risk Group '' patient experience PSA failure ( define least 1 detectable PSA level &gt; 0.2 ng/ml least 2 consecutive increase PSA level baseline least 1 month apart radical prostatectomy ) follow feature : Pathologic T23aN0 disease ( clinical evidence metastasis ) Gleason Score ≤7 , without positive margin Neoadjuvant hormonal therapy prior radical prostatectomy allow , postprostatectomy hormonal therapy prior protocol therapy also allow . Prior chemotherapy , and/or radiation therapy allow least 3 year longer since therapy give time registration , exception previous pelvic radiation NOT allow circumstance . Karnofsky Performance Status ≥ 70 . ( Appendix A ) Hematologic parameter must within follow limit : WBC ≥ 3,000/uL Platelet Count ≥ 100,000/uL Hemoglobin level ≥ 10.0 g/dl Patients history invasive malignancy within last 3 year eligible protocol ; patient NED prior invasive malignancy least 3 year longer eligible trial . Patients history benign tumor pituitary macroadenomas , meningioma , craniopharyngiomas eligible long benign tumor local control regardless time frame . Patients concurrent adequately treat basal cell squamous cell carcinoma skin also eligible protocol . Patients must sign Informed Consent Form . Must concomitant medical , psychological social circumstance would interfere compliance protocol treatment followup . Age ≥ 18 year . Men childbearing potential must willing consent use effective contraception treatment reasonable period thereafter , least 6 month completion protocol therapy . EXCLUSION CRITERIA Subjects meeting exclusion criterion baseline exclude study participation . Patients receive prior pelvic irradiation eligible . Any coexist medical condition preclude full compliance study . Patients active infection know infection HIV . Testing HIV status require . Psychological , familiar , sociological geographical condition would permit compliance study protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Post Operative</keyword>
	<keyword>Radiation</keyword>
	<keyword>Prostatectomy</keyword>
	<keyword>3-D CRT</keyword>
	<keyword>IMRT</keyword>
	<keyword>RT</keyword>
	<keyword>CRT</keyword>
	<keyword>Conformal Radiation Therapy</keyword>
	<keyword>Intensity Modulated Radiation Therapy</keyword>
	<keyword>Hormone</keyword>
	<keyword>Surgery</keyword>
	<keyword>Hormonal Therapy</keyword>
</DOC>